LEXAPRO
ESCITALOPRAM OXALATE
Approval overview LEXAPRO is listed in Drugs@FDA under application 021365 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ESCITALOPRAM OXALATE Form and strength SOLUTION;ORAL - EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBVIE Submission history Latest submission status date: 2024-04-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview LEXAPRO is listed in Drugs@FDA under application 021365 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ESCITALOPRAM OXALATE Form and strength SOLUTION;ORAL - EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBVIE Submission history Latest submission status date: 2024-04-19 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.